Loading…
← CockpitCompetitor Analysis › INDSWFTLAB.NS Ind-Swift Laboratories Ltd.Open in the cockpit ↗

Ind-Swift Laboratories Ltd.INDSWFTLAB.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum leader 97
Mkt cap
$314M
US dollars, full cap
Free float
39%
of shares outstanding
$/day
$3.19M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-7.7 pp
WACC 12.5%
Hurdle
n/a
no reverse DCF
Close · INR₹336.75
1D+1.5%
1W-7.3%
1M-4.3%
3M-2.9%
6M+149.9%
YTD+282.0%
1Y+228.3%
ATR %7.0%
Beta0.56
52w lowhigh21.1% off high

What Ind-Swift Laboratories does

Employees: 1,388

Ind-Swift Laboratories at a glance

Size Ind-Swift Laboratories (INDSWFTLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $314M, the 1045th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹336.75 on 18 Nov 2026.

Performance Over six months the shares gained 149.9%, against -22.6% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 66.4% over the last twelve months (peer median +2.3%); the operating margin is 9.4% (peer median -7.0%).

Valuation It trades at 3.4× enterprise value to sales against a peer median of 4.8× (9th cheapest of 19).

Capital Return on invested capital runs 7.7 points below its cost of capital (12.5% WACC).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026INDSWFTLAB.NS 248Peer median 77
Six months, rebased to 100: Ind-Swift Laboratories against the median of its 20 peers (local-currency closes).

Ind-Swift Laboratories financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹7.53B₹6.28B₹5.64B₹17.1B₹12.1B
Revenue growth—+11%-67%+42%—
Gross profit₹2.57B₹1.12B₹837M₹4.06B₹2.57B
EBITDA₹1.03B₹284M-₹155M₹3.07B₹2.31B
Net income₹836M₹431M₹2.50B₹5.39B₹476M
Free cash flown/a-₹1.06B-₹965M-₹5.07B₹573M
Capital expendituren/a₹877M₹644M₹730M₹128M
Total debt₹214M₹179M₹330M₹2.06B₹8.53B

Quarterly statements and history in the cockpit →

Ind-Swift Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%0%+25%+50%000790INO368AALEMBICLTD301331AVIR005250688302RLMD0021681720MYXINDSWFTLAB.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Ind-Swift Laboratories is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×500×000790INO368AALEMBICLTD6883021875INDSWFTLAB.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ind-Swift Laboratories is the large dot.

Ind-Swift Laboratories competitors and peer comparison

How Ind-Swift Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ind-Swift Laboratories against its 20 peers (data as of 18 Nov 2026)
MeasureINDSWFTLAB.NSPeer medianRank in peer set
1-month return-4.3%-9.4%8th highest of 21
6-month return+149.9%-22.6%2nd highest of 21
Distance from 52-week high-21.1%-40.5%4th highest of 21
Revenue growth (TTM)+66.4%+2.3%2nd highest of 19
Operating margin9.4%-7.0%4th highest of 19
EV / Sales3.4×4.8×9th cheapest of 19
ROIC minus cost of capital-7.7 pp-7.1 pp9th lowest of 18
EV / EBITDA25.0×9.6×2nd most expensive of 6
Net debt / EBITDA-3.5×-1.2×2nd least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%3.4×n/an/a
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%5.6×27.5%-6.4%
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%921.6×n/an/a
Kitazato 368A.TJapan$317M+7%+9%52%3.1×-16.8%+5.4%
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%13.0×44.3%+26.7%
Enwei Pharmaceutical 301331.SZChina$308M-20%-7%5%2.1×14.0%+7.3%
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%1.1×n/an/a
Swedencare SECARE.STSweden$321M-24%+3%7%1.8×6.1%+62.1%
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%21.4×n/an/a
Hinova Pharmaceuticals 688302.SSChina$305M-35%+251%-195%17.1×n/an/a
Relmada Therapeutics RLMDUnited States$305M-60%n/an/an/an/an/a
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%6.2×n/an/a
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%7.4×14.3%-14.0%
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%1.8×-11.5%+10.3%
Honz Pharmaceutical 300086.SZChina$299M-40%-23%-54%7.3×56.0%-12.8%
Zhejiang Shengda Bio-Pharm 603079.SSChina$297M-30%-3%7%2.3×4.6%-0.3%
Hainan Huluwa Pharmaceutical 605199.SSChina$296M-21%-32%-58%4.8×1.4%-4.9%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%1.4×9.2%+6.5%
Mayne Pharma MYX.AXAustralia$333M+155%-6%-14%1.2×19.0%-0.9%
BioDlink International 1875.HKHong Kong$334M-24%-51%-31%4.8×n/an/a

Questions

Which companies are Ind-Swift Laboratories's closest peers?
The cockpit's peer set: Chengdu Huasun Technology (000790.SZ), Inovio Pharmaceuticals (INO), Kitazato (368A.T), Alembic (ALEMBICLTD.NS), Enwei Pharmaceutical (301331.SZ), Atea Pharmaceuticals (AVIR), GC Corp. (005250.KS), Swedencare (SECARE.ST).
Is Ind-Swift Laboratories expensive compared with its peers?
On ev / sales it trades at 3.4× against a peer median of 4.8×, 9th cheapest of 19 in its peer set.
How has Ind-Swift Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +149.9% against -22.6% for the median peer; over one year +228.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.